Stated plainly: 1 mg · two weeks · headache.
I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me suspicious.
My background is quantitative but not chemical, so I can follow an equation more easily than a hand-wave.
Is the standard explanation correct, and if so, what is the evidence for it?
two weeks at 1 mg is 14 days at one dose level — and the arithmetic the question hides is that it also moves every dose above 1 mg back by 14 days. Whether that reduces headache depends on which quantity it tracks. A symptom driven by the dose itself is unchanged by waiting: 1 mg is 1 mg on day 1 and on day 14. A symptom driven by the rate of change has 14 days of no change to settle in, which is the case the hold is actually made for. The distinction is testable on your own record: plot headache against days-since-last-increase rather than against dose, and if the peaks line up with the increases the hold is doing something. Escalation schedules are set by a prescriber, and nothing here is medical advice.
Start with the half-life, because the interval between steps should be at least four half-lives or you are escalating before the previous step has expressed itself.
Titrating downward is available too. Stepping back and holding is a normal adjustment rather than a failure.
| Agent | Start | Step interval | Maintenance range | Max studied |
|---|---|---|---|---|
| Semaglutide (weight management) | 0.25 mg/wk | 4 weeks | 1.7–2.4 mg/wk | 2.4 mg/wk |
| Semaglutide (T2DM) | 0.25 mg/wk | 4 weeks | 0.5–2.0 mg/wk | 2.0 mg/wk |
| Tirzepatide | 2.5 mg/wk | 4 weeks | 5–15 mg/wk | 15 mg/wk |
| Liraglutide (weight management) | 0.6 mg/day | 1 week | 3.0 mg/day | 3.0 mg/day |
| Oral semaglutide | 3 mg/day | 4 weeks | 7–14 mg/day | 50 mg/day (trial) |
Structure is identical across the class: small start, four-week steps, a defined maintenance range, a defined ceiling.
For an agent with a one-week half-life, steady state after a dose change is reached in about four to five weeks. Escalating at two weeks means escalating from a position you have not yet reached, and the resulting exposure is higher than the schedule intends.
Four to five half-lives to steady state is standard first-order pharmacokinetics and gives the four-week interval directly from the one-week half-life.
A schedule described here is a published schedule for a licensed product and is not a recommendation.
Hold rather than escalate while symptoms are active. Always.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsThe honest answer is that going slower costs time and nothing else, since the exposure ceiling is unchanged.
The published semaglutide weight-management schedule steps 0.25, 0.5, 1.0, 1.7 and 2.4 mg at four-week intervals, with 0.25 mg as an initiation step rather than a therapeutic one.
The part that matters: holding a step for eight weeks instead of four is a legitimate approach with no efficacy cost at the destination, and it is what the trials effectively did for anyone who tolerated poorly.
Slower costs time and nothing else. The ceiling is the same.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.